
## **Pneumococcal Vaccination in Adults**

Updated December 2024

Use this algorithm to select the recommended <u>pneumococcal vaccine</u><sup>g</sup> (including timing of doses) in adults who should be vaccinated. For additional guidance, use CDC's PneumoRecs VaxAdvisor App (<u>mobile</u> or <u>web</u> version). At the time of publication, the dose for all pneumococcal vaccines for adults is one single dose (i.e., repeat doses of the same vaccine are not recommended).<sup>1,2</sup>



## **Pneumococcal Vaccination in Adults**

Updated December 2024

- a. **Immunocompromising conditions** include: chronic kidney failure, congenital or acquired asplenia, congenital or acquired immunodeficiencies (includes Bor T- cell deficiency, complement deficiencies, and phagocytic disorders [excluding chronic granulomatous disease]), generalized malignancy, HIV infection, Hodgkin disease, iatrogenic immunosuppression (diseases requiring treatment with systemic corticosteroids [14 days or longer <sup>2</sup>], other immunosuppressive drugs [e.g., chemotherapy], radiotherapy), leukemia, lymphoma, multiple myeloma, nephrotic syndrome, congenital or acquired asplenia; hemoglobinopathies (including sickle cell disease) and solid organ transplant.<sup>2</sup>
- b. **Chronic health conditions increasing pneumococcal disease risk**: alcoholism, chronic liver disease, heart disease (including heart failure, cardiomyopathy), chronic lung disease (including COPD, emphysema, asthma), diabetes, and smoking.<sup>2</sup>
- c. If *Vaxneuvance* is given to a patient naive to all pneumococcal vaccines, a dose of *Pneumovax 23* (or [if *Pneumovax 23* is not available] *Capvaxive* or *Prevnar 20*) is recommended at least one year after *Vaxneuvance* or (for patients with immunocompromising conditions, cochlear implant, or CSF leak can be considered at least eight weeks after *Vaxneuvance*).<sup>2</sup>
- d. Capvaxive, Prevnar 20, or Vaxneuvance should be given  $\geq 1$  year after the last Pneumovax 23 or Prevnar 13 dose. Or, given  $\geq 5$  years after if the patient has received both Pneumovax 23 and Prevnar 13.
- e. Alternatively, for patients with immunocompromising conditions<sup>a</sup> who have had both *Prevnar 13* and two doses [one dose for patients with a cochlear implant or cerebrospinal fluid leak] of *Pneumovax 23*, no additional pneumococcal vaccine can be given. These patients should have their pneumococcal vaccine needs reviewed when they turn 50 years.<sup>2</sup>
- f. Patients 19 to 49 years with chronic health conditions who have had both *Prevnar 13* and *Pneumovax 23* do not require further pneumococcal vaccines. These patients should have their pneumococcal vaccine needs reviewed when they turn 50 years.<sup>2</sup>
- g. PCV20 = Prevnar 20; PCV21 = Capvaxive; PCV15 = Vaxneuvance; PPSV23 = Pneumovax 23; PCV13 = Prevnar 13.

## References

- 1.CDC. Pneumococcal vaccine recommendations. October 26, 2024. <a href="https://www.cdc.gov/pneumococcal/hcp/vaccine-recommendations/index.html">https://www.cdc.gov/pneumococcal/hcp/vaccine-recommendations/index.html</a>. (Accessed October 26, 2024).
- 2. CDC. Pneumococcal vaccine timing for adults. October 2024. <a href="https://www.cdc.gov/pneumococcal/downloads/vaccine-timing-adults-jobaid.pdf">https://www.cdc.gov/pneumococcal/downloads/vaccine-timing-adults-jobaid.pdf</a>? CDC\_AAref\_Val=https://www.cdc.gov/vaccines/vpd/pneumo/downloads/pneumo-vaccine-timing.pdf. (Accessed October 27, 2024).

Users of this resource are cautioned to use their own professional judgment and consult any other necessary or appropriate sources prior to making clinical judgments based on the content of this document. Our editors have researched the information with input from experts, government agencies, and national organizations. Information and internet links in this article were current as of the date of publication.

Copyright © 2024 by Therapeutic Research Center. All Rights Reserved. trchealthcare.com